TRAIL: at the center of drugable anti-tumor pathways.
Fiche publication
Date publication
juillet 2005
Auteurs
Membres identifiés du Cancéropôle Est :
Dr GRONEMEYER Hinrich
Tous les auteurs :
Clarke N, Nebbioso A, Altucci L, Gronemeyer H
Lien Pubmed
Résumé
Molecular analysis, in vivo and in vitro has identified TRAIL as a central component of anti-cancer networks in the cell. More recently, TRAIL has been shown to be involved in the selective apoptosis of AML cells by histone deacetylase inhibitors (HDACi). Here we summarize findings that the TRAIL pathway is a key factor in the apoptotic action of HDACi, as well as, retinoids and retinoid-combinations.
Référence
Cell Cycle. 2005 Jul;4(7):914-8